The special research section of BQ Blue collects quality and in-depth capital and economics research reports from India's leading brokerages, asset managers and research agencies. These reports offer BloombergQuint subscribers the opportunity to broaden their understanding of companies, sectors, and the economy.
Torrent Pharmaceuticals Ltd.'s performance in the first quarter of fiscal 22 was largely in line with our estimates.
The growth momentum in the domestic formulations business was offset by a moderate performance in the US business.
He continues to work on alternate site submissions to reduce the impact of US Food and Drug Administration regulatory issues.
The brand-name generics segment in DF / Latin America / Germany is improving, with ease in the cases of Covid-19.
Torrent Pharma's plan to enter the commercial generics segment would further boost growth opportunities in the DF segment.
Click on the attachment to read the full report:
DISCLAIMER OF LIABILITY
This report is externally authored. BloombergQuint does not guarantee the accuracy of its content nor is it responsible for it in any way. The content of this section does not constitute investment advice. For that, you should always consult an expert based on your individual needs. The opinions expressed in the report are those of the author entity and do not represent the opinions of BloombergQuint.
Users are not licensed to copy, modify or distribute the content without the permission of the original owner.
